<DOC>
	<DOCNO>NCT01838395</DOCNO>
	<brief_summary>The goal clinical research study learn BL-8040 combination cytarabine ( Ara-C ) help control disease patient Acute Myeloid Leukemia ( AML ) relapse respond adequately previous treatment . The safety study drug combination also study .</brief_summary>
	<brief_title>Phase IIa Study Evaluating Safety Efficacy BL-8040 Relapsed/Refractory AML Patients</brief_title>
	<detailed_description>Open-label , multicenter , phase IIa , dose escalate study subject relapsed/refractory AML , define accord WHO criterion ( 1 ) , include subject fail chemotherapy fail previous Autologous Stem Cell Transplantation ( ASCT ) / Allogeneic Stem Cell Transplantation ( AlloSCT ) , provide least 6 month pass transplant . Eligible subject receive subcutaneous ( SC ) injection BL-8040 ( `` monotherapy period '' ) two day ( one injection per day ) follow concurrent administration BL-8040 standard salvage chemotherapy ( `` combine period '' ) 5 day . During `` combined period , '' BL-8040 administer 4 hour prior chemotherapy . The chemotherapy consist cytarabine ( Ara-C ) 1.5 3 g/m2/d per dose ( base age ) , administer intravenously ( IV ) 3 hour , 5 day escalate . The first part study ( Part 1 ) include escalate dose group consider 'escalation phase ' . Six potential dose level ( see Table 1 ) investigate start dose level 1 . Patients accrue conventional 3+3 design . Applying study design , first cohort 3 patient treat dose level 1 evaluate dose escalation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Adult men woman subject age 18 75 , inclusive . 2 . Confirmed diagnosis relapsed/refractory AML ( WHO criteria ) Refractory subject , second consecutive salvage . Relapsed subject include first second relapse . 3 . AML relapse &gt; 6 month since autologous allogeneic stem cell transplantation , provide first second relapse : No active graftversushost disease ( GVHD &gt; grade 1 ) . No treatment high dose steroid GVHD ( 20 mg Prednisolone equivalent , Appendix G ) . No treatment immunosuppressive drug exception low dose cyclosporine tacrolimus ( blood level 0.50.6 µg/mL ) . 4 . Clinical laboratory value follow : WBC &lt; 30,000/mL Blasts PB ≤ 20,000 . Treatment Hydroxyurea permit 24 hr prior BL8040 administration achieve blast count &lt; 20,000 prior enrollment . Creatinine &lt; 1.3 mg/dL ; Creatinine &gt; 1 mg/dL Creatinine clearance &gt; 40 mL/min calculate use CockcroftGault formula . 5 . Women childbearing potential men must agree use approved form contraception ( e.g . oral , transdermal patch , implanted contraceptive , intrauterine device , diaphragm , condom , abstinence surgical sterility ) prior study entry duration study participation 30 day last dose BL8040 . Confirmation female subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . 6 . Subject able willing comply requirement protocol . 7 . Subject able voluntarily provide write informed consent . 1 . Administration conventional chemotherapy within 2 week enrollment date . In event subject receive chemotherapy &gt; 2 week date enrollment , may include provide recover associated nonhematological toxicity ≤ grade 1 . 2 . Life expectancy ≤ 2 month . 3 . Known allergy hypersensitivity test compound , material contraindication test product . 4 . Use investigational device agent within 2 week enrollment date . 5 . Low Performance Status ( ECOG &gt; 2 ; Appendix E ) . 6 . O2 saturation &lt; 92 % ( room air ) , evidence TLS &gt; grade 2 ( accord CairoBishop criterion ( 3 ) ) leukostasis ( 2 ) . 7 . Abnormal liver function test : Serum aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) 2 x upper limit normal ( ULN ) . Serum bilirubin . Total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) , conjugate bilirubin &gt; 0.8 mg/dL . 8 . Left ventricular ejection fraction &lt; 40 % . 9 . History myocardial infarction cerebrovascular accident within 6 month enrollment date . 10 . Presence active , uncontrolled infection . 11 . Known central nervous system disease ( e.g. , Alzheimer 's disease ) . 12 . Acute promyelocytic leukemia . 13 . Exposure high dose AraC within 6 month enrollment . 14 . Subject concurrent , uncontrolled medical condition , laboratory abnormality , psychiatric illness could place him/her unacceptable risk , include , limited : Subject diagnose treat another malignancy within 3 year enrolment , except situ malignancy , lowrisk prostate , skin cervix cancer curative therapy A comorbid condition , view Investigators , render subject high risk treatment complication . 15 . Female subject pregnant breastfeeding . 16 . Prior clinically significant grade 34 nonhematological toxicity high dose AraC grade ≥ 2 neurological toxicity . 17 . Seropositive HIV antibody ( HIV1 HIV2 ) , Hepatitis C antibody ( Hep C Ab ) Hepatitis B carrier ( positive Hepatitis B surface antigen [ HBsAg ] ) . 18 . Unable comply study requirement opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Relapsed Acute Myeloid Leukemia</keyword>
	<keyword>Refractory Acute Myeloid Leukemia</keyword>
</DOC>